RxGen, Miragen Awarded NIH Grant for microRNA Research | GenomeWeb

RxGen and Miragen Therapeutics said this week that they have received a grant from the National Institutes of Health to continue preclinical research on microRNA targeting in cardiovascular disease.

The grant, worth about $720,000, will also be used to support the development of a novel model system of chronic heart failure, according to the companies.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Science this week: CRISPR-based approach to identify gene variants, and more.

Stat News profiles the Wellcome Trust's Jeremy Farrar.

France's research minister tells Nature News that he hopes to simplify the research bureaucracy and improve funding.

A recent study examines how a paper, despite being retracted, can influence its field, Retraction Watch reports.